Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
Latest Information Update: 28 Jul 2022
At a glance
- Drugs Carbetocin (Primary)
- Indications Prader-Willi syndrome
- Focus Registrational; Therapeutic Use
- Acronyms CARE-PWS
- Sponsors Levo Therapeutics
- 18 Jul 2022 Status changed from active, no longer recruiting to completed.
- 19 Jul 2021 Planned End Date changed from 1 Jun 2021 to 1 Dec 2022.
- 23 Mar 2021 Results presented at the 103rd Annual Meeting of the Endocrine Society.